Clinical breakpoints

Setting breakpoints

Breakpoints for phenotypic antimicrobial susceptibility testing have been determined by breakpoint committees and as part of regulatory processes for the approval of new drugs since the 1970s. Dosages, pharmacokinetics, resistance mechanisms, MIC distributions, zone diameter distributions and. more recently. pharmacodynamics and epidemiological cutoff values (ECOFFs) are used in the breakpoint-setting process.

 

Setting breakpoints for new agents (EUCAST SOP)

Revision of breakpoints (EUCAST SOP)

Harmonization of breakpoints for existing antimicrobial agents (EUCAST SOP)

The role of Pk/Pd in setting breakpoints (published in CMI 2012)

MIC wild type distributions and epidemiological cut off values (to be published)